Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced ...

The Cell-Based Assays Market is projected to grow from $35.3 billion in 2024 to $56.3 billion by 2029, at a 9.8% CAGR, driven by demand for drug disc ...

This collaboration comes on the heels of Astellas Pharma's October 2023 memorandum of understanding with BioLabs Global and ...

The global Stem Cell Assays Market is experiencing unprecedented growth, driven by advancements in regenerative medicine, ...

Shah and colleagues take advantage of the presence of maternal and somatic ribosomes in zebrafish and confirm their differential expression during development. The authors convincingly show that ...

Research now reveals a mechanistically distinct vulnerability of BRCA1-deficient cancer cells to gap-inducing DNA nicks. RNA-guided CRISPR-associated transposases (CAST) are natural systems with ...

Stem cells can self-renew indefinitely and, being pluripotent, they can develop into any cell type present in the adult. Much of the focus of stem cell biology is directed at the specification of ...

Virax Biolabs' technology supports vaccine efficacy ... transparency and advance research in protective immunity and T cell dysfunction. Every week, our Whisper Index uncovers five overlooked ...

In neurodegenerative disease research and drug discovery, scientists are increasingly working with complex co-cultures and diverse cell types to model the brain and its cellular mechanisms. This ...

SAN DIEGO - Illumina, Inc. (NASDAQ: NASDAQ:ILMN), known for its next-generation sequencing technology and generating annual revenue of $4.37 billion, has announced a collaboration with Broad Clinical ...

Additionally, presentations will feature streamlined workflows to prepare samples from cell-free DNA and RNA ... For over 50 years, New England Biolabs (NEB) has pioneered the discovery and ...

The division introduces: AdiaVita: A private-label product featuring umbilical cord stem cells. Each unit of AdiaVita guarantees a minimum of 100 million viable cells and 3 trillion exosomes ...